Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AURA CVE:GPH NYSEMKT:IGC NYSE:MRK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAURAAura Biosciences$6.71-5.8%$6.23$4.35▼$12.38$337.30M0.45210,474 shs212,805 shsGPHGraphite OneC$0.95+11.8%C$0.77C$0.64▼C$1.07C$96.19M1.0275,989 shs243,562 shsIGCIGC Pharma$0.36+9.5%$0.32$0.25▼$0.49$26.62M1.45902,172 shs214,616 shsMRKMerck & Co., Inc.$79.97-1.9%$79.37$73.31▼$128.73$200.78B0.3913.50 million shs11.65 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAURAAura Biosciences-5.76%+4.84%+10.00%+25.19%-27.22%GPHGraphite One+11.76%+35.71%+25.00%+3.26%+35.71%IGCIGC Pharma+4.08%-6.05%+18.60%+27.05%+35,699,900.00%MRKMerck & Co., Inc.-1.98%-4.06%+0.89%+2.61%-36.47%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAURAAura Biosciences2.2591 of 5 stars3.61.00.00.01.93.30.0GPHGraphite OneN/AN/AN/AN/AN/AN/AN/AN/AIGCIGC Pharma1.4169 of 5 stars3.50.00.00.00.61.70.0MRKMerck & Co., Inc.4.9954 of 5 stars3.24.05.04.23.52.53.8Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAURAAura Biosciences 3.25Buy$22.00227.87% UpsideGPHGraphite One 0.00N/AN/AN/AIGCIGC Pharma 3.00Buy$3.88985.43% UpsideMRKMerck & Co., Inc. 2.43Hold$108.6935.91% UpsideCurrent Analyst Ratings BreakdownLatest MRK, GPH, IGC, and AURA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/10/2025MRKMerck & Co., Inc.Morgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$99.00 ➝ $98.005/28/2025AURAAura BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$22.005/23/2025AURAAura BiosciencesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$19.005/20/2025MRKMerck & Co., Inc.Cantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Cautious5/14/2025MRKMerck & Co., Inc.CitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$115.00 ➝ $84.004/22/2025MRKMerck & Co., Inc.Cantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$85.00(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAURAAura BiosciencesN/AN/AN/AN/A$3.04 per shareN/AGPHGraphite OneN/AN/AC$0.01 per share94.17C$0.44 per shareN/AIGCIGC Pharma$1.27M22.38N/AN/A$0.08 per share4.46MRKMerck & Co., Inc.$64.17B3.13$9.46 per share8.45$18.33 per share4.36Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAURAAura Biosciences-$86.92M-$1.90N/AN/AN/AN/A-58.63%-49.74%8/14/2025 (Estimated)GPHGraphite One-C$4.90M-C$0.07N/A∞N/AN/A-10.96%-6.61%N/AIGCIGC Pharma-$13M-$0.08N/AN/AN/A-714.16%-122.44%-88.40%N/AMRKMerck & Co., Inc.$17.12B$6.8711.648.080.8327.27%43.23%17.11%7/29/2025 (Estimated)Latest MRK, GPH, IGC, and AURA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025AURAAura Biosciences-$0.47N/AN/AN/AN/AN/A7/29/2025Q2 2025MRKMerck & Co., Inc.$2.03N/AN/AN/A$15.92 billionN/A5/15/2025Q1 2025AURAAura Biosciences-$0.47-$0.55-$0.08-$0.55N/AN/A4/24/2025Q1 2025MRKMerck & Co., Inc.$2.16$2.22+$0.06$2.01$15.59 billion$15.53 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAURAAura BiosciencesN/AN/AN/AN/AN/AGPHGraphite OneN/AN/AN/AN/AN/AIGCIGC PharmaN/AN/AN/AN/AN/AMRKMerck & Co., Inc.$3.244.05%N/A47.16%14 YearsLatest MRK, GPH, IGC, and AURA DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/27/2025MRKMerck & Co., Inc.quarterly$0.814.18%6/16/20256/16/20257/8/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAURAAura BiosciencesN/A11.0611.06GPHGraphite One0.021.090.33IGCIGC Pharma0.021.150.98MRKMerck & Co., Inc.0.691.411.16Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAURAAura Biosciences96.75%GPHGraphite One0.07%IGCIGC Pharma3.87%MRKMerck & Co., Inc.76.07%Insider OwnershipCompanyInsider OwnershipAURAAura Biosciences5.40%GPHGraphite One28.81%IGCIGC Pharma31.48%MRKMerck & Co., Inc.0.13%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAURAAura Biosciences5050.27 million47.55 millionNot OptionableGPHGraphite One20101.25 millionN/ANot OptionableIGCIGC Pharma6179.69 million54.60 millionN/AMRKMerck & Co., Inc.75,0002.51 billion2.51 billionOptionableMRK, GPH, IGC, and AURA HeadlinesRecent News About These CompaniesRep. Julie Johnson Buys Merck & Co., Inc. (NYSE:MRK) StockJuly 19 at 5:13 PM | marketbeat.comMERCK ALERT: Bragar Eagel & Squire, P.C. is Investigating Merck & Co., Inc. ...July 19 at 3:23 PM | gurufocus.comMERCK ALERT: Bragar Eagel & Squire, P.C. is Investigating Merck & Co., Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmJuly 19 at 2:54 PM | globenewswire.comBerkeley Capital Partners LLC Grows Stock Position in Merck & Co., Inc. (NYSE:MRK)July 19 at 11:10 AM | marketbeat.comCopperwynd Financial LLC Has $1.85 Million Stake in Merck & Co., Inc. (NYSE:MRK)July 19 at 10:39 AM | marketbeat.comKestra Private Wealth Services LLC Acquires 10,298 Shares of Merck & Co., Inc. (NYSE:MRK)July 19 at 10:34 AM | marketbeat.comMerck & Co., Inc. (NYSE:MRK) Stock Holdings Decreased by Formidable Asset Management LLCJuly 19 at 8:24 AM | marketbeat.comPrivate Advisor Group LLC Trims Stock Position in Merck & Co., Inc. (NYSE:MRK)July 19 at 8:09 AM | marketbeat.comRep. C. Scott Franklin Sells Merck & Co., Inc. (NYSE:MRK) StockJuly 19 at 8:06 AM | marketbeat.comGot $200? 2 Dividend Stocks to Buy and Hold ForeverJuly 19 at 5:40 AM | fool.comMerck’s (MRK) Dividend History: A Track Record of ConsistencyJuly 19 at 2:45 AM | msn.comMRK - Merck & Co Inc Executives - MorningstarJuly 18 at 9:45 PM | morningstar.comMMerck (MRK) Falls More Steeply Than Broader Market: What Investors Need to KnowJuly 18 at 6:46 PM | zacks.comCenterBook Partners LP Takes Position in Merck & Co., Inc. (NYSE:MRK)July 18 at 11:37 AM | marketbeat.comArcher Investment Corp Has $2.37 Million Stock Holdings in Merck & Co., Inc. (NYSE:MRK)July 18 at 10:27 AM | marketbeat.comSaturna Capital Corp Has $13.04 Million Stock Position in Merck & Co., Inc. (NYSE:MRK)July 18 at 9:27 AM | marketbeat.comPatton Albertson Miller Group LLC Sells 23,005 Shares of Merck & Co., Inc. (NYSE:MRK)July 18 at 9:10 AM | marketbeat.comConcord Wealth Partners Sells 21,280 Shares of Merck & Co., Inc. (NYSE:MRK)July 18 at 8:23 AM | marketbeat.comLivestock Identification Company Evaluation Report 2025 | Merck, Shearwell, Datamars Drive Innovations with Comprehensive Tagging and Tracking SolutionsJuly 18 at 5:06 AM | globenewswire.comMerck & Co., Inc. (NYSE:MRK) Receives $108.69 Consensus Target Price from AnalystsJuly 18 at 3:23 AM | americanbankingnews.comMerck & Co., Inc. (MRK) Presents at HIV Investor Event TranscriptJuly 17 at 7:01 PM | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMRK, GPH, IGC, and AURA Company DescriptionsAura Biosciences NASDAQ:AURA$6.71 -0.41 (-5.76%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$6.86 +0.15 (+2.16%) As of 07/18/2025 06:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.Graphite One CVE:GPHC$0.95 +0.10 (+11.76%) As of 07/18/2025 03:41 PM EasternGraphite One Inc. operates as mineral exploration company in the United States. The company holds interest in the Graphite Creek property that consists of 135 mining claims located on the Seward Peninsula, Alaska. The company was formerly known as Graphite One Resources Inc. and changed its name to Graphite One Inc. in February 2019. Graphite One Inc. was incorporated in 2006 and is headquartered in Vancouver, Canada.IGC Pharma NYSEMKT:IGC$0.36 +0.03 (+9.48%) Closing price 07/18/2025 03:58 PM EasternExtended Trading$0.34 -0.02 (-5.04%) As of 07/18/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease. The company's lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.Merck & Co., Inc. NYSE:MRK$79.97 -1.55 (-1.90%) Closing price 07/18/2025 03:59 PM EasternExtended Trading$80.11 +0.14 (+0.17%) As of 07/18/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
